area, severe cognitive impairment); and
• positive response to an intrathecal trial.
Given that delivery of medications into the subarachnoid space carries risks beyond those associated with the actual medications, the decision to proceed with this therapy must be carefully undertaken. Procedural risks range from the mild, such as post-dural puncture headache, to the potentially catastrophic, such as neuraxial infection or hematoma.
Adverse effects attributable to the medications are class-dependent but can be severe, including respiratory depression, seizures, weakness, hallucination, or suicidal ideation. The risks of both the procedure and medication(s) to be delivered must be considered and balanced against the risks of a patient's current therapy and untreated pain. However, an inherent shortcoming is that the development of some adverse effects in the long term may not be predicted by the success of a short-term trial (i.e. tolerance, edema, and hyperalgesia with opioid therapy). Despite the potential risks of intrathecal therapy, in the proper setting it can play an important role in the amelioration of refractory neuropathic pain.
Opioids
The discovery of opioid receptors in the central nervous system was reported in several studies in 1973. [5] [6] [7] This discovery led to experimentation with intrathecal morphine in animals and, ultimately, the first reported use of intrathecal opioids by Wang and colleagues in 1979. 8, 9 Following the success noted in Wang's study (all eight patients with refractory cancer-related pain noted resolution of pain with intrathecal morphine), the use of intrathecal opioids in treating a variety of pain conditions has blossomed.
Found in high concentrations in the dorsal horns of the spinal cord, opioid receptors are broadly classified into several subtypes to include mu, delta, and kappa. 10 The mu receptor is the most clinically relevant as it mediates the analgesic effects of commonly used agonists such as morphine, hydromorphone, and fentanyl. Pre-synaptic binding of opioid agonists leads to decreased release of pro-nociceptive neurotransmitters (substance P and calcitonin gene-related peptide), while post-synaptic binding yields increased threshold to action potential via neuronal hyperpolarization.
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The clinical effects of intrathecal opioids are dependent not only on their affinity for the opioid receptor but also on their movement and solubility within the cerebrospinal fluid. Among opioids suitable for intrathecal administration, morphine is the most hydrophilic, followed by hydromorphone. Higher levels of hydrophilicity allow greater and faster rostral spread within the cerebrospinal fluid and delay systemic spread.
Conversely, the lipophilic characteristics of fentanyl and sufentanil result in greater systemic absorption and decreased movement within the spinal column. These properties must be taken into account when selecting an agent, as lipophilic agents need to be delivered more proximally to the targeted area than their hydrophilic counterparts. 12 The first clinical trial researching the effects of intrathecal opioids on chronic pain was published by Smith et al. 13 
Gamma-aminobutyric Acid Agonists
Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter widely distributed throughout the nervous system. Activation of GABA Animal studies assessing the toxicity of intrathecal midazolam have yielded conflicting results, with approximately half reporting neurotoxicity. 34 Deleterious effects have been observed with as little as a single dose, but many studies have shown no pathologic effects after continuous usage, prompting some to conclude that intrathecal midazolam is no more neurotoxic than normal saline. 35, 36 In a cohort study evaluating the effects of adding 2 mg of midazolam to local anesthetic in 1,100 patients undergoing spinal anesthesia, Tucker et al. 37 found no increase in post-operative neurologic symptoms over local anesthetic alone.
Fewer GABA-B agonists are commercially available, but baclofen has shown to be efficacious when given intrathecally to treat spasticity, CRPS, and central pain secondary to stroke or spinal cord injury (SCI). Whereas intrathecal baclofen is currently a first-line agent for the treatment of spasticity secondary to SCI, multiple sclerosis, and other disorders, recent studies have been able to distinguish between the analgesic and spasmolytic properties. These effects are not reversed by the opioid antagonist naloxone, suggesting that GABAergic analgesia occurs via a separate pathway not shared by endogenous opiates. Baclofen is currently considered a fourth-line treatment for chronic pain. 28 In a randomized, double-blind trial, seven women with CRPS were given intrathecal bolus injections of baclofen 25, 50, or 75 μg, or saline. 38 No statistical difference was found between the 25 μg and saline injections, Critics of baclofen analgesia argue that the pain reductions observed are merely the result of elimination of spasm-related pain, but a study conducted by Herman and colleagues 40 demonstrated suppression of neuropathic pain that was temporally distinct from spasm-related pain.
In these patients, the suppression and reappearance of dysesthetic pain after a bolus of intrathecal baclofen occurred distinctly from that of spasm-related pain. No difference was noted in evoked pain in these patients. These results were supported by Taira et al., 41 who found that nine of 14 patients with central pain secondary to stroke or SCI experienced significant reductions in spontaneous pain, allodynia, and hyperalgesia for up to 24 hours following intrathecal baclofen bolus.
In addition to alleviating central pain, intrathecal baclofen has shown efficacy when used to treat neuropathic pain secondary to failed back surgery syndrome (FBSS), amputation, and plexopathy. 42 Lind and 
Local Anesthetics
Local anesthetics are sodium-channel-blocking agents that reversibly decrease the rate of depolarization and repolarization in neuromembranes, preventing action potential initiation and inhibiting signal conduction. Local anesthetics block the transmission of all neurons, not just the A-delta and C fibers responsible for the transmission of pain sensation. These agents have been the cornerstone of neuraxial analgesia for surgical pain for decades, but it was not until the 1990s that they were critically evaluated for chronic pain. 46 Few studies to date have sought to isolate local anesthetic efficacy in neuropathic pain.
Most research evaluating intrathecal local anesthetics have used them in conjunction with opioids. Some authors have concluded that the combination provides synergistic effects after the observation that co-administration of bupivacaine diminishes morphine dose progression during long-term intrathecal administration. 47 Bupivacaine, the most commonly studied intrathecal local anesthetic, appears to be most effective in patients with neuropathic pain. 48 In a prospective cohort trial, Nitescu et al. 49 In therapeutic concentrations, local anesthetics are relatively non-toxic and disrupt neurotransmission in a predictable fashion. The dose escalation of intrathecal local anesthetics is limited by adverse effects.
Common adverse effects of intrathecal local anesthetics include numbness, paresthesias, weakness, and bowel/bladder dysfunction.
High levels of systemic bupivacaine have been associated with cardiotoxicity, which is difficult to reverse. The incidence of adverse effects can be diminished by using combination therapy with opioids and other agents. In clinical practice, the typical range of intrathecal bupivacaine is less than 35 mg/day. 
Calcium Channel Blockers
Calcium A subsequent study by Rauck et al. 57 was designed to determine whether the prevalence of adverse effects could be decreased by using a lower maximum dose and slower titration schedule. Two hundred and twenty patients with refractory non-malignant pain were randomized to either placebo or ziconotide. The most prevalent diagnosis was and hallucinations being among the most common. However, the enhanced benefit of co-administering opioids and ziconotide must be weighed against the decreased stability of ziconotide when mixed with opioids, which is accelerated at higher concentrations. In addition to the above studies, several case reports have documented good relief for refractory facial pain with intrathecal ziconotide. [60] [61] [62] Table 3 summarizes common agent-specific adverse effects. The most studied and only US Food and Drug Administration-approved alpha-2 agonist for intrathecal use is clonidine. Intrathecal clonidine has been studied extensively in animal models and has been shown to safely alleviate neuropathic pain in a dose-dependent manner. 67 In human subjects, clonidine has been used and studied as both a bolus administration and continuous infusion. While trials have shown promise using epidural clonidine infusion as monotherapy in treating CRPS, intrathecal clonidine infusions are typically combined with a local anesthetic or opioid. 68 Some studies of intrathecal clonidine infusion have yielded mixed results and recommend further study. 69 Siddall and colleagues 70 There is no evidence that intrathecal clonidine is neurotoxic, and it does not cause respiratory depression. The most common adverse effects of clonidine are hypotension, sedation, bradycardia, and nausea. The hypotension associated with clonidine administration may be more pronounced at lower doses, since at higher doses this effect Intrathecal Drug Delivery for Neuropathic Pain
Alpha-2 Agonists
is antagonized by direct peripheral vasoconstriction. If a patient is receiving long-term therapy with clonidine, abrupt cessation can result in rebound hypertension.
An alpha-2 agonist with higher receptor affinity than clonidine is dexmedetomidine. An early study evaluating the effects of intrathecal dexmedetomidine on self-mutilation (autotomy), a behavior that may indicate the presence of neuropathic pain, demonstrated that rats injected with dexmedetomidine after unilateral sciatic nerve section autotomized significantly less than those receiving saline or morphine. 72 However, dexmedetomidine was unsuccessful in preventing autotomy when injected prophylactically. In another trial studying the effects of intrathecal dexmedetomidine in rats following spinal nerve ligation, dexmedetomidine dose-dependently decreased spontaneous locomotor activity, a behavior believed to signify allodynia. 73 In humans, intrathecal dexmedetomidine has not been studied for chronic pain, but a double-blind study performed in 60 patients undergoing transurethral resection of the prostate found that the addition of either intrathecal dexmedetomidine or clonidine to bupivacaine shortened the onset of sensory and motor blockade, prolonged the duration of the block, and preserved hemodynamic stability. 74 Tizanidine is another alpha-2 receptor agonist that has shown positive results in animal models of neuropathic pain. Kawamata et al. 75 compared the effects of intrathecal tizanidine and clonidine in rats following sciatic nerve ligation. Dose-dependent reversal of thermal and mechanical hyperalgesia was observed for both drugs, with the highest dosages (5 μg tizanidine and 3 μg clonidine) producing statistically significant effects. Compared with clonidine, tizanidine was associated with a faster onset of action and fewer adverse effects. Tizanidine can occasionally cause liver damage. 76 Its intrathecal administration has not been studied in humans. 
Steroids
Corticosteroids have profound and complex anti-inflammatory properties.
They inhibit the release of an array of pro-inflammatory mediators (prostaglandins, leukotrienes, cytokines, tissue necrosis factor alpha, and others) from multiple types of leukocytes. 77, 78 Once used routinely for the treatment of back pain and lumbar radiculopathy, intrathecal injection of steroids fell from favor in the mid-1980s following its implication in the development of adhesive arachnoiditis. 79, 80 Although the preservative polyethylene glycol was blamed in several studies, the intrathecal administration of steroids was nevertheless largely abandoned in favor of the epidural route. 81 However, intrathecal steroid injections remain an alternative treatment for refractory post-herpetic neuralgia (PHN).
PHN is a painful neuropathic condition that can occur in up to 10 % of patients following an acute outbreak of herpes zoster. After initial exposure, the varicella zoster virus may lay dormant in the dorsal root ganglia and become activated months to years later. 82 The 86 and zoster vaccine. 87 If preventive measures are not instituted or fail, the treatment of PHN can be challenging; it has been estimated that roughly 2 % of patients with PHN will have ongoing pain five years following their initial outbreak. 88 In those in whom conventional therapies, such as membrane stabilizers, antidepressants, opioids, and topical analgesics, fail, intrathecal steroids can be considered.
Kikuchi and colleagues 89 performed a prospective randomized trial comparing intrathecal with epidural methylprednisolone in 25 patients with chronic PHN pain. Patients were treated four times at one-week intervals and were followed for 24 weeks after treatment. Global pain relief was superior at all data points in the intrathecal group, with 12 of 13 patients reporting good to excellent analgesia throughout the study compared with only two of 12 patients in the epidural group.
Of the biochemical markers analyzed, the only statistically significant difference was decreased levels of interleukin-8 in the intrathecal group one week post-treatment and at 24 weeks.
In a prospective, randomized, placebo-controlled study by Kotani et al., longer-lasting analgesia than the other two groups. For all treatments, the maximum benefit was observed between one and three weeks. 30 The potential risk of adhesive arachnoiditis must be taken into account when opting to pursue intrathecal steroid administration. Preservative-free methylprednisolone formulations are not commercially available, but a recent report by Candido et al. described a technique by which they were able to decrease the amount of polyethylene glycol extracted from vials of steroid by an average of 85 % without decreasing the amount of steroid withdrawn. 91 However, as the precise causative agent remains unclear, it is prudent to reserve this treatment for those who have failed safer and more conventional treatments, and to limit the number of intrathecal injections to four.
Conclusions
Since its introduction more than 30 years ago, the use of intrathecal therapy to provide analgesia has grown steadily. Significant advances have been made with regard to delivery systems, selection criteria, and the discovery of new drugs that act via non-opioid receptor sites.
Opioids remain the most commonly used intrathecal analgesics, and the evidence supporting their use in cancer-related pain remains strong.
For neuropathic pain, intrathecal opioids may provide long-term benefit in carefully selected individuals, but this must be weighed against the cumulative risks of long-term intrathecal opioid therapy, including hyperalgesia and endocrine dysfunction. There is very strong evidence to support the use of baclofen as a treatment for spasticity-related pain, and moderate evidence to support its use for neuropathic pain. Although limited by its narrow therapeutic index and high cost, there is good evidence that ziconotide is effective for neuropathic pain. Bupivacaine has a long history of safe use as a spinal analgesic and may provide significant benefit to individuals as an adjunct agent. Because of its opioid-sparing properties and ability to attenuate the sympathetic response, clonidine may be especially useful in patients with neuropathic pain. Future studies should focus on cost-effectiveness, better identification of phenotypes that may respond to intrathecal treatment, and methods to reduce adverse effects and complications. n
